• 1
    Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry 2000;57:101230.
  • 2
    Munarriz R, Kim NN, Goldstein I, Traish AM. Biology of female sexual function. Urol Clin North Am 2002;29:68593.
  • 3
    Nappi R, Salonia A, Traish AM, Van Lunsen RH, Vardi Y, Kodiglu A, Goldstein I. Clinical biologic pathophysiologies of women's sexual dysfunction. J Sex Med 2005;2:425.
  • 4
    Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002;77:S428.
  • 5
    Speroff L, Mark A. Fritz, clinical gynecologic endocrinology and infertility. 7th edition. Philadelphia: Lippincott Williams & Wilkins; 2004.
  • 6
    Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: Focus on findings from the Melbourne Women's Midlife Health Project. Hum Reprod Update 2007;13:55965.
  • 7
    Schwenkhagen A. Hormonal changes in menopause and implications on sexual health. J Sex Med 2007;4(3 suppl):2206.
  • 8
    Burger H. The menopausal transition-endocrinology. J Sex Med 2008;5:226673.
  • 9
    Rosen R, et al., eds. Androgen Insufficiency in women: The Princeton Conference. Fertil Steril 2002;77(4 suppl).
  • 10
    Farage M, Maibach H. Lifetime changes in the vulva and vagina. Arch Gynecol Obstet 2006;273:195202.
  • 11
    Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: A literature review. Menopause 2004;11:12030.
  • 12
    Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007;14:S2040.
  • 13
    Genazzani AR, Monteleone P, Gambacciani M. Hormonal influence on the central nervous system. Maturitas 2002;43:S117.
  • 14
    McEwen BS. Clinical review 108: The molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metab 1999;84:17907.
  • 15
    Bachmann G. Urogenital ageing: An old problem newly recognized. Maturitas 1995;22:S15.
  • 16
    Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004;49:292303.
  • 17
    Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:76274.
  • 18
    Davison SL, Bell RJ, LaChina M, Holden SL, Davis SR. Sexual function in well women: Stratification by sexual satisfaction, hormone use, and menopause status. J Sex Med 2008;5:121422.
  • 19
    Giraldi A, Marson L, Nappi R, Pfaus J, Traish AM, Vardi Y, Goldstein I. Physiology of female sexual function: Animal models. J Sex Med 2004;1:23753.
  • 20
    Traish AM, Kim SW, Stankovic M, Goldstein I, Kim NN. Testosterone increases blood flow and expression of androgen and estrogen receptors in the rat vagina. J Sex Med 2007;4:60919.
  • 21
    Nappi RE. New attitudes to sexuality in the menopause: Clinical evaluation and diagnosis. Climacteric 2007;10:S1058.
  • 22
    Nappi RE, Baldaro Verde J, Polatti F, Genazzani AR, Zara C. Self-reported sexual symptoms in women attending menopause clinics. J Obstet Gynecol Invest 2002;53:1817.
  • 23
    Sarrel PM. Sexuality and menopause. Obstet Gynecol 1990;75:26S35S.
  • 24
    Cutler WB, Garcia CM, McCoy N. Perimenopausal sexuality. Arch Sex Behav 1987;16:22534.
  • 25
    Modelska K, Litwack S, Ewing SK, Yaffe K. Endogenous estrogen levels affect sexual function in elderly post-menopausal women. Maturitas 2004;49:12433.
  • 26
    Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:3518.
  • 27
    Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001;76:45660.
  • 28
    Dennerstein L, Lehert P, Burger H. The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition. Fertil Steril 2005;84:17480.
  • 29
    Gallicchio L, Schilling C, Tomic D, Miller SR, Zacur H, Flaws JA. Correlates of sexual functioning among mid-life women. Climacteric 2007;10:13242.
  • 30
    Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: A review of double-blind, randomized controlled trials. Menopause 2004;11:74965.
  • 31
    Nappi RE. Sexuality and menopause. In: ErkkolaR, ed. The menopause. Philadelphia, PA: Elsevier; 2006:14354.
  • 32
    Goldstein I. Current management strategies of the postmenopausal patient with sexual health problems. J Sex Med 2007;4(3 suppl):23553.
  • 33
    Board of the International Menopause Society, Pines A, Sturdee DW, Birkhäuser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:18194.
  • 34
    North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:16882.
  • 35
    North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: Position statement of The North American Menopause Society. Menopause 2004;11:1133.
  • 36
    Genazzani AR, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. Climacteric 2007;10:8896.
  • 37
    Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: Systematic review of placebo-controlled trials. Am J Obstet Gynecol 2003;188:28693.
  • 38
    Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behaviour in postmenopause. J Womens Health Gend Based Med 2000;9:S2532.
  • 39
    Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:522633.
  • 40
    Dennerstein L, Leventhal Alexander J. Estradiol and sexual function in postmenopausal women: Differential effects of mode of administration and dose. Menopause 2006;13:7213.
  • 41
    Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991;72:33643.
  • 42
    Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: Effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels. Gynecol Endocrinol 2005;20:1449.
  • 43
    Nachtigall LE, Raju U, Banerjee S, Wan L, Levitz M. Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: Associations with sex hormone-binding globulin, estradiol, and estrone levels. Menopause 2000;7:24350.
  • 44
    Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:98594.
  • 45
    Simon JA, Snabes MC. Menopausal hormone therapy for vasomotor symptoms: Balancing the risks and benefits with ultra-low doses of estrogen. Expert Opin Investig Drugs 2007;16:200520.
  • 46
    Scarabin PY, Oger E, Plu-Bureau G, Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:42832.
  • 47
    Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004;292:15817.
  • 48
    Nathorst-Boos J, Wiklund I, Mattsson LA, Sandin K, Von Schoultz B. Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obstet Gynecol Scand 1993;72:65660.
  • 49
    Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: A double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:82430.
  • 50
    Huang A, Yaffe K, Vittinghoff E, Kuppermann M, Addis I, Hanes V, Quan J, Grady D. The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. Am J Obstet Gynecol 2008;198:265, e1–7.
  • 51
    Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991;72:33643.
  • 52
    Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:106579.
  • 53
    Simon JA, Reape KZ, Wininger S, Hait H. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertil Steril 2008;90:11328.
  • 54
    Lobo RA. Progestogen metabolism. J Reprod Med 1999;44:S14852.
  • 55
    Nathorst-Boos J, Hammar M. Effect on sexual life—A comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:1520.
  • 56
    Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, Helmond FA, Van Lunsen RH, Palacios S, Norman RJ, Mulder RJ, Davis SR, LISA Study Investigators. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: Results of a randomized active-controlled trial. J Sex Med 2008;5:64656.
  • 57
    Schneider HP. Androgens and antiandrogens. Ann N Y Acad Sci 2003;997:292306.
  • 58
    Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52:S4652.
  • 59
    Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 2005;50:98104.
  • 60
    Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency—A pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:1217.
  • 61
    Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:5847.
  • 62
    Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17Beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:15661.
  • 63
    Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:2937.
  • 64
    Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:8392.
  • 65
    North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:35569.
  • 66
    Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: An update on recent clinical findings. Obstet Gynecol Surv 2008;63:16381.
  • 67
    De Gooyer ME, Kleyn GT, Smits KC, Ederveen AG, Verheul HA, Kloosterboer HJ. Tibolone: A compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001;183:5562.
  • 68
    Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999;17:148892.
  • 69
    Fornander T, Rutqvist LE, Wilking N. Effects of tamoxifen on the female genital tract. Ann N Y Acad Sci 1991;622:46976.
  • 70
    Schover LR. The impact of breast cancer on sexuality, body image, and intimate relationships. CA Cancer J Clin 1991;41:11220.
  • 71
    Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:50114.
  • 72
    Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:426171.
  • 73
    Berglund G, Nystedt M, Bolund C, Sjoden PO, Rutquist LE. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: A prospective randomized study. J Clin Oncol 2001;19:278896.
  • 74
    Moen MD, Keating GM. Raloxifene: A review of its use in the prevention of invasive breast cancer. Drugs 2008;68:205983.
  • 75
    Voss S, Quail D, Dawson A, Bäckström T, Aguas F, Erenus M, The HS, Bonnar J, De Geyter C, Hunter M, Nickelsen T, Euralox Investigators Group. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: Effects on compliance and quality of life. BJOG 2002;109:87485.
  • 76
    Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL III, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:274251.
  • 77
    Modugno F, Ness RB, Ewing S, Cauley JA. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. Obstet Gynecol 2003;101:35361.
  • 78
    Natale V, Albertazzi P, Missiroli N, Pedrini D, Salgarello M. Effects of raloxifene on mood, sleep, libido and cognitive function in postmenopausal healthy women: A pilot study. Maturitas 2004;48:5963.
  • 79
    Sharma S, Albertazzi P, Bottazzi M. The long-term effect of raloxifene on the genitourinary tract. Climacteric 2007;10:2448.
  • 80
    Pinkerton JV, Shifren JL, La Valleur J, Rosen A, Roesinger M, Siddhanti S. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003;10:4552.
  • 81
    Parsons A, Merritt D, Rosen A, Heath H III, Siddhanti S, Plouffe L Jr. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:34652.
  • 82
    Kenemans P, Speroff L. International Tibolone Consensus Group. Tibolone: Clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:218.
  • 83
    Suzuki T, Sasano H, Andersson S, Mason JI. 3beta-hydroxysteroid dehydrogenase/delta5–>4-isomerase activity associated with the human 17beta-hydroxysteroid dehydrogenase type 2 isoform. J Clin Endocrinol Metab 2000;85:366972.
  • 84
    De Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003;68:2130.
  • 85
    Doren M, Rubig A, Coelnigh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:5549.
  • 86
    Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:16270.
  • 87
    Rymer J, Chapman MG, Fogelman I, Wilson PO. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994;18:12733.
  • 88
    Nappi RE, Ferdeghini F, Sampaolo P, Vaccaro P, De Leonardis C, Albani F, Salonia A, Polatti F. Clitoral circulation in postmenopausal women with sexual dysfunction: A pilot randomized study with hormone therapy. Maturitas 2006;55:28895.
  • 89
    Palacios S, Menendez C, Jurado AR, Castano R, Vargas JC. Changes in sex behaviour after menopause: Effects of tibolone. Maturitas 1995;22:15561.
  • 90
    Nathorst-Boos J, Hammar M. Effect on sexual life—A comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:1520.
  • 91
    Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E, Pons F, Balasch J, Vanrell JA. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:1618.
  • 92
    Laan E, Van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001;4:2841.
  • 93
    Somunkiran A, Erel CT, Demirci F, Senturk ML. The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: A randomized, cross-over study. Maturitas 2007;56:618.
  • 94
    Soliman NF, Hillard TC. Hormone replacement therapy in women with past history of endometriosis. Climacteric 2006;9:32535.
  • 95
    Nijland EA, Weijmar Schultz WC, Davis SR. Effects of tibolone and raloxifene on health-related quality of life and sexual function. Maturitas 2007;58:16473.
  • 96
    Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R, LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697708.